Spero Q2 FY26 net loss widens to $9.6 million; revenue posts no revenue
SPRO•Program updates
FDA cleared Utebzi for adult cUTIs; GSK expects U.S. availability by end-2026.
Licensed Phase 2-ready SP001 from Innovent outside Greater China; plans a Phase 2 study in IgG4-related disease.
Cash position and runway
Cash totaled $50.8 million at June 30; $105 million royalty financing extends runway into the second half of 2029.
Q2 results and expense trends
Spero Therapeutics posted a Q2 net loss of $9.6 million, widening from a $1.7 million loss a year earlier; loss per share widened to $0.16.
Revenue was nil, versus $14.2 million in the prior-year quarter.
R&D expense fell to $3.4 million from $10.7 million, due to lower Utebzi Phase 3 activity and reduced personnel costs.
G&A expense rose to $6.5 million from $5.9 million, on higher legal and business development costs.
